

Roger G Pertwee

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8725700/roger-g-pertwee-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

180
papers

20,451
citations

69
h-index

142
g-index

214
ext. papers

22,500
ext. citations

6.3
avg, IF

7.28
L-index

#	Paper	IF	Citations
180	CB1 receptor binding sites for NAM and PAM: a first approach for studying, new n-butyl-diphenylcarboxamides as allosteric modulators. <i>European Journal of Pharmaceutical Sciences</i> , 2021 , 169, 106088	5.1	1
179	Effects on the Post-translational Modification of H3K4Me3, H3K9ac, H3K9Me2, H3K27Me3, and H3K36Me2 Levels in Cerebral Cortex, Hypothalamus and Pons of Rats after a Systemic Administration of Cannabidiol: A Preliminary Study. <i>Central Nervous System Agents in Medicinal Chemistry</i> , 2021 , 21, 142-147	1.8	2
178	Discovery of a Biased Allosteric Modulator for Cannabinoid 1 Receptor: Preclinical Anti-Glaucoma Efficacy. <i>Journal of Medicinal Chemistry</i> , 2021 , 64, 8104-8126	8.3	6
177	Therapeutic Potential of Cannabidiol, Cannabidiolic Acid, and Cannabidiolic Acid Methyl Ester as Treatments for Nausea and Vomiting. <i>Cannabis and Cannabinoid Research</i> , 2021 , 6, 266-274	4.6	3
176	Variously substituted 2-oxopyridine derivatives: Extending the structure-activity relationships for allosteric modulation of the cannabinoid CB2 receptor. <i>European Journal of Medicinal Chemistry</i> , 2021 , 211, 113116	6.8	2
175	Assessing the treatment of cannabidiolic acid methyl ester: a stable synthetic analogue of cannabidiolic acid on c-Fos and NeuN expression in the hypothalamus of rats. <i>Journal of Cannabis Research</i> , 2021 , 3, 31	2.5	
174	Design, synthesis, and pharmacological profiling of cannabinoid 1 receptor allosteric modulators: Preclinical efficacy of C2-group GAT211 congeners for reducing intraocular pressure. <i>Bioorganic and Medicinal Chemistry</i> , 2021 , 50, 116421	3.4	1
173	THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein-coupled receptors. <i>British Journal of Pharmacology</i> , 2021 , 178 Suppl 1, S27-S156	8.6	46
172	Synthetic bioactive olivetol-related amides: The influence of the phenolic group in cannabinoid receptor activity. <i>Bioorganic and Medicinal Chemistry</i> , 2020 , 28, 115513	3.4	0
171	Anticancer effects of n-3 EPA and DHA and their endocannabinoid derivatives on breast cancer cell growth and invasion. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2020 , 156, 102024	2.8	15
170	Disease-associated polymorphisms within the conserved ECR1 enhancer differentially regulate the tissue-specific activity of the cannabinoid-1 receptor gene promoter; implications for cannabinoid pharmacogenetics. <i>Human Mutation</i> , 2020 , 41, 291-298	4.7	3
169	Sleep and neurochemical modulation by cannabidiolic acid methyl ester in rats. <i>Brain Research Bulletin</i> , 2020 , 155, 166-173	3.9	5
168	Application of Fluorine- and Nitrogen-Walk Approaches: Defining the Structural and Functional Diversity of 2-Phenylindole Class of Cannabinoid 1 Receptor Positive Allosteric Modulators. <i>Journal of Medicinal Chemistry</i> , 2020 , 63, 542-568	8.3	30
167	PSNCBAM-1 analogs: Structural evolutions and allosteric properties at cannabinoid CB1 receptor. <i>European Journal of Medicinal Chemistry</i> , 2020 , 203, 112606	6.8	1
166	Indomethacin Enhances Type 1 Cannabinoid Receptor Signaling. <i>Frontiers in Molecular Neuroscience</i> , 2019 , 12, 257	6.1	5
165	ΔTetrahydrocannabivarin has potent anti-nicotine effects in several rodent models of nicotine dependence. <i>British Journal of Pharmacology</i> , 2019 , 176, 4773-4784	8.6	7
164	Disruption of an enhancer associated with addictive behaviour within the cannabinoid receptor-1 gene suggests a possible role in alcohol intake, cannabinoid response and anxiety-related behaviour. <i>Psychoneuroendocrinology</i> , 2019 , 109, 104407	5	9

163	Identification of the First Synthetic Allosteric Modulator of the CB Receptors and Evidence of Its Efficacy for Neuropathic Pain Relief. <i>Journal of Medicinal Chemistry</i> , 2019 , 62, 276-287	8.3	28
162	THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptors. <i>British Journal of Pharmacology</i> , 2019 , 176 Suppl 1, S21-S141	8.6	391
161	Cannabinoid receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. <i>IUPHAR/BPS Guide To Pharmacology CITE</i> , 2019 , 2019,	1.7	4
160	Pharmacology and potential therapeutic uses of some cannabinoids. <i>Future Neurology</i> , 2019 , 14, FNL28	1.5	
159	Fatty acid suppression of glial activation prevents central neuropathic pain after spinal cord injury. <i>Pain</i> , 2019 , 160, 2724-2742	8	3
158	The First Photochromic Affinity Switch for the Human Cannabinoid Receptor 2. <i>Advanced Therapeutics</i> , 2018 , 1, 1700032	4.9	9
157	Positive Allosteric Modulation of Cannabinoid Receptor Type 1 Suppresses Pathological Pain Without Producing Tolerance or Dependence. <i>Biological Psychiatry</i> , 2018 , 84, 722-733	7.9	72
156	Cannabidiolic acid methyl ester, a stable synthetic analogue of cannabidiolic acid, can produce 5-HT receptor-mediated suppression of nausea and anxiety in rats. <i>British Journal of Pharmacology</i> , 2018 , 175, 100-112	8.6	35
155	Enantiospecific Allosteric Modulation of Cannabinoid 1 Receptor. <i>ACS Chemical Neuroscience</i> , 2017 , 8, 1188-1203	5.7	63
154	Synthesis, radio-synthesis and in vitro evaluation of terminally fluorinated derivatives of HU-210 and HU-211 as novel candidate PET tracers. <i>Organic and Biomolecular Chemistry</i> , 2017 , 15, 2086-2096	3.9	5
153	The Pharmacology and Therapeutic Potential of Plant Cannabinoids 2017 , 207-225		8
152	The In Vivo Effects of the CB-Positive Allosteric Modulator GAT229 on Intraocular Pressure in Ocular Normotensive and Hypertensive Mice. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2017 , 33, 582-590	2.6	17
151	Big conductance calcium-activated potassium channel openers control spasticity without sedation. <i>British Journal of Pharmacology</i> , 2017 , 174, 2662-2681	8.6	15
150	Exploring the Benzimidazole Ring as a Substitution for Indole in Cannabinoid Allosteric Modulators. <i>Cannabis and Cannabinoid Research</i> , 2016 , 1, 196-201	4.6	2
149	The Displacement Binding Assay Using Human Cannabinoid CB2 Receptor-Transfected Cells. <i>Methods in Molecular Biology</i> , 2016 , 1412, 57-63	1.4	
148	The Cyclic AMP Assay Using Human Cannabinoid CB2 Receptor-Transfected Cells. <i>Methods in Molecular Biology</i> , 2016 , 1412, 85-93	1.4	4
147	Effect of cannabis on glutamate signalling in the brain: A systematic review of human and animal evidence. <i>Neuroscience and Biobehavioral Reviews</i> , 2016 , 64, 359-81	9	89
146	Novel Electrophilic and Photoaffinity Covalent Probes for Mapping the Cannabinoid 1 Receptor Allosteric Site(s). <i>Journal of Medicinal Chemistry</i> , 2016 , 59, 44-60	8.3	46

145	Mapping Cannabinoid 1 Receptor Allosteric Site(s): Critical Molecular Determinant and Signaling Profile of GAT100, a Novel, Potent, and Irreversibly Binding Probe. <i>ACS Chemical Neuroscience</i> , 2016 , 7, 776-98	5.7	30
144	Pure Δ^9 -tetrahydrocannabivarin and a Cannabis sativa extract with high content in Δ^9 -tetrahydrocannabivarin inhibit nitrite production in murine peritoneal macrophages. <i>Pharmacological Research</i> , 2016 , 113, 199-208	10.2	15
143	CB2 cannabinoid receptor agonist enantiomers HU-433 and HU-308: An inverse relationship between binding affinity and biological potency. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015 , 112, 8774-9	11.5	40
142	Modulation of food consumption and sleep-wake cycle in mice by the neutral CB1 antagonist ABD459. <i>Behavioural Pharmacology</i> , 2015 , 26, 289-303	2.4	17
141	Tricyclic Fused Pyrazoles with a Δ^1 -2,3-Triazole Substituent in Position 3 Are Nanomolar CB1 Receptor Ligands. <i>Synthesis</i> , 2015 , 47, 817-826	2.9	8
140	Endocannabinoids and Their Pharmacological Actions. <i>Handbook of Experimental Pharmacology</i> , 2015 , 231, 1-37	3.2	163
139	Increasing levels of the endocannabinoid 2-AG is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. <i>Experimental Neurology</i> , 2015 , 273, 36-44	5.7	46
138	Are cannabidiol and (Δ^9)-tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. <i>British Journal of Pharmacology</i> , 2015 , 172, 737-53	8.6	327
137	The phytocannabinoid, Δ^9 -tetrahydrocannabivarin, can act through 5-HT _{2A} receptors to produce antipsychotic effects. <i>British Journal of Pharmacology</i> , 2015 , 172, 1305-18	8.6	32
136	Inhibition of colon carcinogenesis by a standardized Cannabis sativa extract with high content of cannabidiol. <i>Phytomedicine</i> , 2014 , 21, 631-9	6.5	70
135	Pyrazoles with a Δ^1 -[N-(4-fluorobutyl)-1,2,3-triazole] substituent in position 3 are nanomolar CB1 receptor ligands. <i>Journal of Fluorine Chemistry</i> , 2014 , 167, 184-191	2.1	5
134	Early phytocannabinoid chemistry to endocannabinoids and beyond. <i>Nature Reviews Neuroscience</i> , 2014 , 15, 757-64	13.5	204
133	Structure-affinity relationships and pharmacological characterization of new alkyl-resorcinol cannabinoid receptor ligands: Identification of a dual cannabinoid receptor/TRPA1 channel agonist. <i>Bioorganic and Medicinal Chemistry</i> , 2014 , 22, 4770-83	3.4	11
132	Known Pharmacological Actions of Nine Nonpsychotropic Phytocannabinoids 2014 , 137-156		14
131	In-vivo pharmacological evaluation of the CB1-receptor allosteric modulator Org-27569. <i>Behavioural Pharmacology</i> , 2014 , 25, 182-5	2.4	49
130	Elevating endocannabinoid levels: pharmacological strategies and potential therapeutic applications. <i>Proceedings of the Nutrition Society</i> , 2014 , 73, 96-105	2.9	64
129	Known Pharmacological Actions of Delta-9-Tetrahydrocannabinol and of Four Other Chemical Constituents of Cannabis that Activate Cannabinoid Receptors 2014 , 115-136		18
128	Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT _{1A} receptors. <i>Neuropharmacology</i> , 2013 , 75, 155-63	5.5	45

127	Characterization of cannabinoid receptor ligands in tissues natively expressing cannabinoid CB2 receptors. <i>British Journal of Pharmacology</i> , 2013 , 169, 887-99	8.6	17
126	Cannabinoids and omega-3/6 endocannabinoids as cell death and anticancer modulators. <i>Progress in Lipid Research</i> , 2013 , 52, 80-109	14.3	65
125	CB(1) receptor allosteric modulators display both agonist and signaling pathway specificity. <i>Molecular Pharmacology</i> , 2013 , 83, 322-38	4.3	91
124	Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?. <i>British Journal of Clinical Pharmacology</i> , 2013 , 75, 323-33	3.8	204
123	Cannabidiolic acid prevents vomiting in <i>Suncus murinus</i> and nausea-induced behaviour in rats by enhancing 5-HT1A receptor activation. <i>British Journal of Pharmacology</i> , 2013 , 168, 1456-70	8.6	105
122	Investigations on the 4-quinolone-3-carboxylic acid motif. 6. Synthesis and pharmacological evaluation of 7-substituted quinolone-3-carboxamide derivatives as high affinity ligands for cannabinoid receptors. <i>European Journal of Medicinal Chemistry</i> , 2012 , 58, 30-43	6.8	17
121	Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington's disease: role of CB1 and CB2 receptors. <i>ACS Chemical Neuroscience</i> , 2012 , 3, 400-6	5.7	71
120	Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2012 , 367, 3353-63	5.8	244
119	8-Tetrahydrocannabivarin prevents hepatic ischaemia/reperfusion injury by decreasing oxidative stress and inflammatory responses through cannabinoid CB2 receptors. <i>British Journal of Pharmacology</i> , 2012 , 165, 2450-61	8.6	29
118	AM630 behaves as a protean ligand at the human cannabinoid CB2 receptor. <i>British Journal of Pharmacology</i> , 2012 , 165, 2561-74	8.6	44
117	Investigations on the 4-quinolone-3-carboxylic acid motif part 5: modulation of the physicochemical profile of a set of potent and selective cannabinoid-2 receptor ligands through a bioisosteric approach. <i>ChemMedChem</i> , 2012 , 7, 920-34	3.7	24
116	Lipoxin A4 is an allosteric endocannabinoid that strengthens anandamide-induced CB1 receptor activation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 20781-2	11.5	14
115	Modulation of L-Elysophosphatidylinositol/GPR55 mitogen-activated protein kinase (MAPK) signaling by cannabinoids. <i>Journal of Biological Chemistry</i> , 2012 , 287, 91-104	5.4	106
114	Structural and pharmacological analysis of O-2050, a putative neutral cannabinoid CB(1) receptor antagonist. <i>European Journal of Pharmacology</i> , 2011 , 651, 96-105	5.3	24
113	Interaction between non-psychotropic cannabinoids in marijuana: effect of cannabigerol (CBG) on the anti-nausea or anti-emetic effects of cannabidiol (CBD) in rats and shrews. <i>Psychopharmacology</i> , 2011 , 215, 505-12	4.7	57
112	Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease. <i>Journal of Neuroscience Research</i> , 2011 , 89, 1509-18	4.4	69
111	Phytocannabinoids beyond the Cannabis plant - do they exist?. <i>British Journal of Pharmacology</i> , 2010 , 160, 523-9	8.6	123
110	The plant cannabinoid Delta9-tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice. <i>British Journal of Pharmacology</i> , 2010 , 160, 677-87	8.6	94

109	Cannabinoid receptor-dependent and -independent anti-proliferative effects of omega-3 ethanolamides in androgen receptor-positive and -negative prostate cancer cell lines. <i>Carcinogenesis</i> , 2010 , 31, 1584-91	4.6	114
108	Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists. <i>Current Medicinal Chemistry</i> , 2010 , 17, 1360-81	4.3	237
107	Investigations on the 4-quinolone-3-carboxylic acid motif. 3. Synthesis, structure-affinity relationships, and pharmacological characterization of 6-substituted 4-quinolone-3-carboxamides as highly selective cannabinoid-2 receptor ligands. <i>Journal of Medicinal Chemistry</i> , 2010 , 53, 5915-28	8.3	35
106	In vitro and in vivo pharmacological characterization of two novel selective cannabinoid CB(2) receptor inverse agonists. <i>Pharmacological Research</i> , 2010 , 61, 349-54	10.2	22
105	WIN55,212-2 induced deficits in spatial learning are mediated by cholinergic hypofunction. <i>Behavioural Brain Research</i> , 2010 , 208, 584-92	3.4	41
104	International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. <i>Pharmacological Reviews</i> , 2010 , 62, 588-631	22.5	1159
103	Cannabidiol targets mitochondria to regulate intracellular Ca ²⁺ levels. <i>Journal of Neuroscience</i> , 2009 , 29, 2053-63	6.6	164
102	Emerging strategies for exploiting cannabinoid receptor agonists as medicines. <i>British Journal of Pharmacology</i> , 2009 , 156, 397-411	8.6	339
101	Synthetic and plant-derived cannabinoid receptor antagonists show hypophagic properties in fasted and non-fasted mice. <i>British Journal of Pharmacology</i> , 2009 , 156, 1154-66	8.6	103
100	Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes. <i>Journal of Medicinal Chemistry</i> , 2009 , 52, 3001-9	8.3	17
99	Therapeutic Applications for Agents that Act at CB1 and CB2 Receptors 2009 , 361-392		9
98	The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. <i>British Journal of Pharmacology</i> , 2008 , 153, 199-215	8.6	1082
97	Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond. <i>Addiction Biology</i> , 2008 , 13, 147-59	4.6	224
96	Cannabinoid-mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2008 , 193, 120-9	3.5	82
95	CB1 and CB2 Receptor Pharmacology 2008 , 91-99		2
94	Inhibition of human neutrophil chemotaxis by endogenous cannabinoids and phytocannabinoids: evidence for a site distinct from CB1 and CB2. <i>Molecular Pharmacology</i> , 2008 , 73, 441-50	4.3	111
93	Neuroprotective effects of the nonpsychoactive cannabinoid cannabidiol in hypoxic-ischemic newborn piglets. <i>Pediatric Research</i> , 2008 , 64, 653-8	3.2	108
92	Hippocampal endocannabinoids inhibit spatial learning and limit spatial memory in rats. <i>Psychopharmacology</i> , 2008 , 198, 551-63	4.7	46

91	The Therapeutic Potential of Drugs that Target Cannabinoid Receptors or Modulate the Tissue Levels or Actions of Endocannabinoids 2008 , 637-686		0
90	Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. <i>Nature Medicine</i> , 2007 , 13, 492-7	50.5	292
89	The psychoactive plant cannabinoid, Delta9-tetrahydrocannabinol, is antagonized by Delta8- and Delta9-tetrahydrocannabivarin in mice in vivo. <i>British Journal of Pharmacology</i> , 2007 , 150, 586-94	8.6	68
88	GPR55: a new member of the cannabinoid receptor clan?. <i>British Journal of Pharmacology</i> , 2007 , 152, 984-6	8.6	151
87	Interactions of cannabidiol with endocannabinoid signalling in hippocampal tissue. <i>European Journal of Neuroscience</i> , 2007 , 25, 2093-102	3.5	25
86	Cannabinoids and multiple sclerosis. <i>Molecular Neurobiology</i> , 2007 , 36, 45-59	6.2	64
85	Anti-inflammatory property of the cannabinoid receptor-2-selective agonist JWH-133 in a rodent model of autoimmune uveoretinitis. <i>Journal of Leukocyte Biology</i> , 2007 , 82, 532-41	6.5	85
84	Novel compounds that interact with both leukotriene B4 receptors and vanilloid TRPV1 receptors. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006 , 316, 955-65	4.7	22
83	The pharmacology of cannabinoid receptors and their ligands: an overview. <i>International Journal of Obesity</i> , 2006 , 30 Suppl 1, S13-8	5.5	375
82	First "hybrid" ligands of vanilloid TRPV1 and cannabinoid CB2 receptors and non-polyunsaturated fatty acid-derived CB2-selective ligands. <i>FEBS Letters</i> , 2006 , 580, 568-74	3.8	23
81	Scopolamine and MK801-induced working memory deficits in rats are not reversed by CBD-rich cannabis extracts. <i>Behavioural Brain Research</i> , 2006 , 168, 307-11	3.4	25
80	Differential effects of cannabis extracts and pure plant cannabinoids on hippocampal neurones and glia. <i>Neuroscience Letters</i> , 2006 , 408, 236-41	3.3	26
79	Cannabidiol-induced intracellular Ca ²⁺ elevations in hippocampal cells. <i>Neuropharmacology</i> , 2006 , 50, 621-31	5.5	69
78	Effect of sublingual application of cannabinoids on intraocular pressure: a pilot study. <i>Journal of Glaucoma</i> , 2006 , 15, 349-53	2.1	88
77	Cannabinoid pharmacology: the first 66 years. <i>British Journal of Pharmacology</i> , 2006 , 147 Suppl 1, S163-78.6	78.6	435
76	Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. <i>Life Sciences</i> , 2005 , 76, 1307-24	6.8	352
75	Influence of the degree of unsaturation of the acyl side chain upon the interaction of analogues of 1-arachidonoylglycerol with monoacylglycerol lipase and fatty acid amide hydrolase. <i>Biochemical and Biophysical Research Communications</i> , 2005 , 337, 104-9	3.4	42
74	Evidence that (-)-7-hydroxy-4'-dimethylheptyl-cannabidiol activates a non-CB(1), non-CB(2), non-TRPV1 target in the mouse <i>vas deferens</i> . <i>Neuropharmacology</i> , 2005 , 48, 1139-46	5.5	25

73	The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. <i>AAPS Journal</i> , 2005 , 7, E625-54	3.7	166
72	Synthesis of long-chain amide analogs of the cannabinoid CB1 receptor antagonist N-(piperidinyl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716) with unique binding selectivities and pharmacological activities. <i>Bioorganic and Medicinal Chemistry</i> , 2005 , 13, 5463-74	3.4	26
71	Evidence that the plant cannabinoid Delta9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist. <i>British Journal of Pharmacology</i> , 2005 , 146, 917-26	8.6	125
70	Allosteric modulation of the cannabinoid CB1 receptor. <i>Molecular Pharmacology</i> , 2005 , 68, 1484-95	4.3	371
69	Cannabidiol as a potential medicine 2005 , 47-65		8
68	Inhibition of monoacylglycerol lipase and fatty acid amide hydrolase by analogues of 2-arachidonoylglycerol. <i>British Journal of Pharmacology</i> , 2004 , 143, 774-84	8.6	69
67	6"-AzidoheX-2"-yne-cannabidiol: a potential neutral, competitive cannabinoid CB1 receptor antagonist. <i>European Journal of Pharmacology</i> , 2004 , 487, 213-21	5.3	56
66	Pharmacological and therapeutic targets for Δ^9 tetrahydrocannabinol and cannabidiol. <i>Euphytica</i> , 2004 , 140, 73-82	2.1	43
65	Differential effects of THC- or CBD-rich cannabis extracts on working memory in rats. <i>Neuropharmacology</i> , 2004 , 47, 1170-9	5.5	88
64	Effects of delta9-THC and WIN-55,212-2 on place preference in the water maze in rats. <i>Psychopharmacology</i> , 2003 , 166, 40-50	4.7	26
63	Pharmacophoric requirements for the cannabinoid side chain. Probing the cannabinoid receptor subsite at C1'. <i>Journal of Medicinal Chemistry</i> , 2003 , 46, 3221-9	8.3	46
62	Inverse agonism at cannabinoid receptors. <i>International Congress Series</i> , 2003 , 1249, 75-86		5
61	(-)-Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferens. <i>European Journal of Pharmacology</i> , 2002 , 456, 99-106	5.3	113
60	Cannabinoids and multiple sclerosis 2002 , 95, 165-74		140
59	Localisation of cannabinoid CB(1) receptor immunoreactivity in the guinea pig and rat myenteric plexus. <i>Journal of Comparative Neurology</i> , 2002 , 448, 410-22	3.4	129
58	Pharmacological characterization of the anandamide cyclooxygenase metabolite: prostaglandin E2 ethanolamide. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002 , 301, 900-7	4.7	94
57	New developments in the pharmacology of cannabinoids. <i>Pharmacochemistry Library</i> , 2002 , 249-258		
56	Synthesis and structure-activity relationships of amide and hydrazide analogues of the cannabinoid CB(1) receptor antagonist N-(piperidinyl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716). <i>Journal of Medicinal Chemistry</i> , 2002 , 45, 2708-19	8.3	88

55	Structure-activity relationship for the endogenous cannabinoid, anandamide, and certain of its analogues at vanilloid receptors in transfected cells and vas deferens. <i>British Journal of Pharmacology</i> , 2001 , 132, 631-40	8.6	194
54	A possible role of lipoxygenase in the activation of vanilloid receptors by anandamide in the guinea-pig bronchus. <i>British Journal of Pharmacology</i> , 2001 , 134, 30-7	8.6	76
53	Endocannabinoids control spasticity in a multiple sclerosis model. <i>FASEB Journal</i> , 2001 , 15, 300-2	0.9	330
52	Cannabinoid receptors and pain. <i>Progress in Neurobiology</i> , 2001 , 63, 569-611	10.9	581
51	Actions of cannabinoid receptor ligands on rat cultured sensory neurones: implications for antinociception. <i>Neuropharmacology</i> , 2001 , 40, 221-32	5.5	158
50	Agonist-induced internalization and trafficking of cannabinoid CB1 receptors in hippocampal neurons. <i>Journal of Neuroscience</i> , 2001 , 21, 2425-33	6.6	138
49	Comparison of novel cannabinoid partial agonists and SR141716A in the guinea-pig small intestine. <i>British Journal of Pharmacology</i> , 2000 , 129, 645-52	8.6	42
48	O-1057, a potent water-soluble cannabinoid receptor agonist with antinociceptive properties. <i>British Journal of Pharmacology</i> , 2000 , 129, 1577-84	8.6	43
47	Cannabinoids control spasticity and tremor in a multiple sclerosis model. <i>Nature</i> , 2000 , 404, 84-7	50.4	462
46	Inhibition of nitric oxide production in RAW264.7 macrophages by cannabinoids and palmitoylethanolamide. <i>European Journal of Pharmacology</i> , 2000 , 401, 121-30	5.3	92
45	Neuropharmacology and therapeutic potential of cannabinoids. <i>Addiction Biology</i> , 2000 , 5, 37-46	4.6	62
44	Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity. <i>FEBS Letters</i> , 2000 , 483, 52-6	3.8	290
43	Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery and development. <i>Expert Opinion on Investigational Drugs</i> , 2000 , 9, 1553-71	5.9	157
42	Development of agonists, partial agonists and antagonists in the β -Tetrahydrocannabinol series. <i>Tetrahedron</i> , 1999 , 55, 13907-13926	2.4	18
41	Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630. <i>British Journal of Pharmacology</i> , 1999 , 126, 665-72	8.6	314
40	Structural determinants of the partial agonist-inverse agonist properties of 6'-azidohept-2'-yne- Δ^8 -tetrahydrocannabinol at cannabinoid receptors. <i>British Journal of Pharmacology</i> , 1999 , 128, 735-43	8.6	47
39	Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. <i>Journal of Medicinal Chemistry</i> , 1999 , 42, 769-76	8.3	402
38	Prescribing Cannabinoids for Multiple Sclerosis. <i>CNS Drugs</i> , 1999 , 11, 327-334	6.7	6

37	Evidence for the presence of CB1 cannabinoid receptors on peripheral neurones and for the existence of neuronal non-CB1 cannabinoid receptors. <i>Life Sciences</i> , 1999 , 65, 597-605	6.8	61
36	Design and synthesis of the CB1 selective cannabinoid antagonist AM281: a potential human SPECT ligand. <i>AAPS PharmSci</i> , 1999 , 1, E4		59
35	Cannabinoid Receptors and Their Ligands in Brain and Other Tissues 1999 , 177-185		2
34	Pharmacology of Cannabinoid Receptor Ligands. <i>Current Medicinal Chemistry</i> , 1999 , 6, 635-664	4.3	361
33	Comparison of cannabinoid binding sites in guinea-pig forebrain and small intestine. <i>British Journal of Pharmacology</i> , 1998 , 125, 1345-51	8.6	36
32	Correlation between cannabinoid mediated effects on paired pulse depression and induction of long term potentiation in the rat hippocampal slice. <i>Neuropharmacology</i> , 1998 , 37, 1123-30	5.5	51
31	Interactions between synthetic vanilloids and the endogenous cannabinoid system. <i>FEBS Letters</i> , 1998 , 436, 449-54	3.8	126
30	The bioactive conformation of aminoalkylindoles at the cannabinoid CB1 and CB2 receptors: insights gained from (E)- and (Z)-naphthylidene indenenes. <i>Journal of Medicinal Chemistry</i> , 1998 , 41, 5177-87 ³	8.3	51
29	Evidence that cannabinoid-induced inhibition of electrically evoked contractions of the myenteric plexus - longitudinal muscle preparation of guinea-pig small intestine can be modulated by Ca ²⁺ and camp. <i>Canadian Journal of Physiology and Pharmacology</i> , 1998 , 76, 340-346	2.4	27
28	Evidence that cannabinoid-induced inhibition of electrically evoked contractions of the myenteric plexus - longitudinal muscle preparation of guinea-pig small intestine can be modulated by Ca ²⁺ and camp. <i>Canadian Journal of Physiology and Pharmacology</i> , 1998 , 76, 340-346	2.4	4
27	The perceived effects of smoked cannabis on patients with multiple sclerosis. <i>European Neurology</i> , 1997 , 38, 44-8	2.1	215
26	Importance of the C-1 substituent in classical cannabinoids to CB2 receptor selectivity: synthesis and characterization of a series of O,2-propano-delta 8-tetrahydrocannabinol analogs. <i>Journal of Medicinal Chemistry</i> , 1997 , 40, 3312-8	8.3	15
25	Evidence for the presence of CB2-like cannabinoid receptors on peripheral nerve terminals. <i>European Journal of Pharmacology</i> , 1997 , 339, 53-61	5.3	128
24	Action of delta-9-tetrahydrocannabinol on GABA(A) receptor-mediated responses in a grease-gap recording preparation of the rat hippocampal slice. <i>Neuropharmacology</i> , 1997 , 36, 1387-92	5.5	18
23	Synthesis and pharmacological comparison of dimethylheptyl and pentyl analogs of anandamide. <i>Journal of Medicinal Chemistry</i> , 1997 , 40, 3626-34	8.3	57
22	Inhibition by cannabinoid receptor agonists of acetylcholine release from the guinea-pig myenteric plexus. <i>British Journal of Pharmacology</i> , 1997 , 121, 1557-66	8.6	116
21	Evidence that methyl arachidonyl fluorophosphonate is an irreversible cannabinoid receptor antagonist. <i>British Journal of Pharmacology</i> , 1997 , 121, 1716-20	8.6	46
20	Pharmacology of cannabinoid CB1 and CB2 receptors 1997 , 74, 129-80		1074

19	Evidence for the presence of cannabinoid CB1 receptors in mouse urinary bladder. <i>British Journal of Pharmacology</i> , 1996 , 118, 2053-8	8.6	101
18	Further evidence for the presence of cannabinoid CB1 receptors in guinea-pig small intestine. <i>British Journal of Pharmacology</i> , 1996 , 118, 2199-205	8.6	134
17	Further evidence for the presence of cannabinoid CB1 receptors in mouse vas deferens. <i>European Journal of Pharmacology</i> , 1996 , 296, 169-72	5.3	32
16	Agonist-antagonist characterization of 6'-cyanohept-2'-yne-delta 8-tetrahydrocannabinol in two isolated tissue preparations. <i>European Journal of Pharmacology</i> , 1996 , 315, 195-201	5.3	38
15	Prevention by the cannabinoid antagonist, SR141716A, of cannabinoid-mediated blockade of long-term potentiation in the rat hippocampal slice. <i>British Journal of Pharmacology</i> , 1995 , 115, 869-70	8.6	74
14	Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. <i>Biochemical Pharmacology</i> , 1995 , 50, 83-90	6	2266
13	A preliminary investigation of the mechanisms underlying cannabinoid tolerance in the mouse vas deferens. <i>European Journal of Pharmacology</i> , 1995 , 272, 67-72	5.3	16
12	Effect of phenylmethylsulphonyl fluoride on the potency of anandamide as an inhibitor of electrically evoked contractions in two isolated tissue preparations. <i>European Journal of Pharmacology</i> , 1995 , 272, 73-8	5.3	58
11	Pharmacological characterization of three novel cannabinoid receptor agonists in the mouse isolated vas deferens. <i>European Journal of Pharmacology</i> , 1995 , 284, 241-7	5.3	55
10	Effect of delta 9-tetrahydrocannabinol on circling in rats induced by intranigral muscimol administration. <i>European Journal of Pharmacology</i> , 1995 , 282, 251-4	5.3	13
9	AM630, a competitive cannabinoid receptor antagonist. <i>Life Sciences</i> , 1995 , 56, 1949-55	6.8	111
8	(R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. <i>Journal of Medicinal Chemistry</i> , 1994 , 37, 1889-93	8.3	296
7	Effects of two endogenous fatty acid ethanolamides on mouse vasa deferentia. <i>European Journal of Pharmacology</i> , 1994 , 259, 115-20	5.3	44
6	The action of synthetic cannabinoids on the induction of long-term potentiation in the rat hippocampal slice. <i>European Journal of Pharmacology</i> , 1994 , 259, R7-8	5.3	55
5	delta 9-Tetrahydrocannabinol and anandamide enhance the ability of muscimol to induce catalepsy in the globus pallidus of rats. <i>European Journal of Pharmacology</i> , 1993 , 250, 205-8	5.3	45
4	The evidence for the existence of cannabinoid receptors. <i>General Pharmacology</i> , 1993 , 24, 811-24		74
3	Brain levels and relative potency of the 1,2-dimethylheptyl analogue of delta1-tetrahydrocannabinol in mice. <i>Biochemical Pharmacology</i> , 1974 , 23, 3017-27	6	2
2	Relative pharmacological potency in mice of optical isomers of delta 1-tetrahydrocannabinol. <i>Biochemical Pharmacology</i> , 1974 , 23, 439-46	6	29

1 The function of the endocannabinoid system 23-34